Keystone Resort Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2005



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Roles of TGF-ß in Disease Pathogenesis: Novel Therapeutic Strategies (C4)


Organizer(s) Anita B. Roberts, Michael B. Sporn and John M. McPherson
March 28—April 2, 2005
Keystone Resort • Keystone, Colorado USA
Abstract Deadline: Nov 29, 2004
Late Abstract Deadline:
Scholarship Deadline:
Early Registration Deadline: Jan 28, 2005

Supported by The Director's Fund

Summary of Meeting:
Elucidation of the signal transduction pathways of TGF-ß has heralded an exciting new era enabling insights into molecular mechanisms of this multifunctional molecule in both normal adult physiology and disease pathogenesis, including especially wound healing, fibrosis, carcinogenesis and immune cell dysfunction. Characterization of the receptor kinases and identification of the Smad signaling pathway has identified new molecular targets and led to development of novel inhibitors of the pathway. Increased understanding of the biochemistry of TGF-ß itself has also enabled development of anti-ligand approaches. Our goal for this conference is to bring together researchers focused on the basic biochemistry of TGF-ß and on the use of animal models to elucidate its roles in disease pathogenesis and researchers from Biotech/Pharma who are developing new drugs based on the TGF-ß pathway to both enhance our insights into mechanisms of action of TGF-ß and provide novel therapeutic approaches for clinical treatment of disease.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


MONDAY, MARCH 28

15:00—19:30
Registration

Shavano Peak Foyer
18:30—19:30
Refreshments

Shavano Peak Foyer
19:30—20:30
Keynote Address
Meeting has ended...abstracts no longer viewable online.

Red Cloud/Shavano
Joan Massagué, Memorial Sloan Kettering Cancer Center, USA
The Logic of TGFbeta Signaling


TUESDAY, MARCH 29

07:00—08:00
Breakfast

Grays
08:00—11:00
New Molecular Targets in TGF-ß Signaling
Meeting has ended...abstracts no longer viewable online.

Longs
* Edward B. Leof, Mayo Clinic, USA
Smad-Independent TGFbeta Signaling: potential Targets for the Treatment of Fibrotic Disease

Jeffrey L. Wrana, Mount Sinai Hospital, Canada
High THroughput Biology and TGFbeta Signaling

Fang Liu, Rutgers University, USA
Inhibition of Smad Antiproliferative Function by CDK Phosphorylation

Steven Dooley, Medical Faculty Mannheim, University of Heidelberg, Germany
Short Talk: Identification of Id1 as Critical Mediator in TGF-ß-Induced Transdifferentiation of Hepatic Stellate Cells

Jeremy Naftali Rich, Cleveland Clinic, USA
Short Talk

09:20—09:40
Coffee Break

Longs Foyer
11:00—13:00
Poster Setup

Grays
13:00—22:00
Poster Viewing

Grays
16:30—17:00
Coffee & Snacks Available

Longs Foyer
17:00—19:00
Role of TGF-ß in Inflammation/ Fibrosis I
Meeting has ended...abstracts no longer viewable online.

Longs
* Michael B. Sporn, Dartmouth Medical School, USA

Anita B. Roberts, National Institutes of Health, USA
Smad3 as a Target in TGF-ß-Mediated Epithelial-to-Mesenchymal Transition, Fibrosis and Metastasis

Christoph Becker, Friedrich Alexander University of Erlangen-Nürnberg, Germany
TGF-ß Dependent T-Cell Regulation in Colitis and Colitis-Associated Colon Cancer

Jack Gauldie, McMaster University, Canada
TGFbeta and Smad3: Linking Inflammation, Fibrosis, and Emphazema

Joanne E. Murphy-Ullrich, University of Alabama at Birmingham, USA
Short Talk: Thrombospondin 1-Dependent TGFbeta Activation in Fibrotic Complications of Diabetes and Hypertension

19:00—20:00
Social Hour

Crestone Peak
19:30—22:00
Poster Session 1

Grays

WEDNESDAY, MARCH 30

07:00—08:00
Breakfast

Grays
08:00—11:00
Role of TGF-ß in Carcinogenesis I
Meeting has ended...abstracts no longer viewable online.

Longs
Lalage M. Wakefield, NCI, National Institutes of Health, USA
'Mechanisms Underlying the Dual Role of TGF-ßs in Breast Cancer: Insights into Tumor Suppressor Mechanisms

* Harold L. Moses, Vanderbilt University, USA
Stromal/Epithelial Interactions in the Role of TGF-ß in Carcinogenesis

Caroline S. Hill, Francis Crick Institute, UK
Modulation of the TGF-ß/Smad Signaling Pathway in Tumorigenesis

Lopa Mishra, George Washington University, USA
Short Talk: Critical Interactions Between TGF-ß Signaling/ELF, and E-Cadherin/ß-catenin Mediated Tumor Suppression

LuZhe Sun, University of Texas Health Science Center, USA
Short Talk: Blockade of Transforming Growth Factor-ß (TGFß) Signaling Inhibits Breast Cancer Metastasis to Bone in an Experimental Animal Model of Bone Metastasis

09:20—09:40
Coffee Break

Longs Foyer
11:00—13:00
Poster Setup

Grays
13:00—22:00
Poster Viewing

Grays
16:30—17:00
Coffee & Snacks Available

Longs Foyer
17:00—19:00
Role of TGF-ß in Carcinogenesis II
Meeting has ended...abstracts no longer viewable online.

Longs
Theresa A. Guise, Indiana University, USA
Role of TGF-beta in Osteolytic Metastases of Breast Cancer

* Kohei Miyazono, University of Tokyo, Japan
Regulation of TGF-ß Signaling by Inhibitory Smads and Cancer

John J. Letterio, National Cancer Institute, National Institutes of Health, USA
Smad Signaling in T Lymphocytes: Roles in Lymphoid and Epithelial Neoplasia

Jan Pinkas, Genzyme Corporation, USA
Short Talk: Active Treatment with a TGF-ß Neutralizing Antibody Enhances Survival in a Syngeneic Model of Disseminated Breast Cancer with Metastasis to Bone

19:00—20:00
Social Hour

Crestone Peak
19:30—22:00
Poster Session 2

Grays

THURSDAY, MARCH 31

07:00—08:00
Breakfast

Grays
08:00—11:00
Role of TGF-ß in Inflammation/Fibrosis II
Meeting has ended...abstracts no longer viewable online.

Longs
Sushil G. Rane, NIDDK, National Institutes of Health, USA
Short Talk: Function of TGFbeta Signaling in Insulin Synthesis, Secretion and Function

Fernando López-Casillas, Universidad Nacional Autónoma de México, Mexico
Recombinant Soluble Betaglycan and Cyclooxygenase Inhibitors Effectively Control Pulmonary Tuberculosis

José Luis Pablos, Hospital 12 de Octubre, Spain
Short Talk: Topical Application of a Peptide Inhibitor of TGF-ß1 Ameliorates Bleomycin Induced Skin Fibrosis

* Erwin P. Böttinger, Mount Sinai School of Medicine, USA
TGF-ß and Kidney Disease: Epithelial Apoptosis Before Fibrosis

Ariela Benigni, Istituto di Ricerche Farmacologiche Mario Negri, Italy
Role of Anti-TGF-ß Antibodies in the Treatment of Renal Injury

09:20—09:40
Coffee Break

Longs Foyer
11:00—13:00
Poster Setup

Grays
13:00—22:00
Poster Viewing

Grays
16:30—17:00
Coffee & Snacks Available

Longs Foyer
17:00—19:00
TGF-ß in Response to Cellular Injury
Meeting has ended...abstracts no longer viewable online.

Longs
* Mark W.J. Ferguson, Science Foundation Ireland, Ireland

Mary Helen Barcellos-Hoff, New York School of Medicine, USA
TGF-β1 is a Key Mediator of the Cellular DNA Damage Response to Ionizing Radiation

Denis Vivien, University of Caen, Cyceron, France
Neuroprotection Induced by TGFbeta Signaling

Kunxin Luo, University of California, Berkeley, USA
Mechanisms that Regulate Sno N Activity in Fibroblasts and Epithelial Cells

David Danielpour, Case Western Reserve University, USA
Short Talk: IGF-I and Akt Suppress TGF-ß/Smad3 Signals through Both Akt kinase/mTOR-Dependent and Akt kinase-Independent Mechanisms.

19:00—20:00
Social Hour

Crestone Peak
19:30—22:00
Poster Session 3

Grays

FRIDAY, APRIL 1

07:00—08:00
Breakfast

Grays
08:00—11:00
Therapeutic Strategies based on TGF-ß or Antagonists
Meeting has ended...abstracts no longer viewable online.

Longs
* John M. McPherson, Genzyme Corporation, USA
Therapeutic Application of TGF-ß Antibodies for the Treatment of Pathological Fibrosis

Mark W.J. Ferguson, Science Foundation Ireland, Ireland
Prevention and Reduction of Scarring in Man by Local Injection of TGFβ3

Karl-Hermann Schlingensiepen, Antisense Pharma GmbH, Germany
Targeted Tumor Therapy with the TGF-beta2 Antisense Compound AP 12009

Ellen H. Filvaroff, Genentech, Inc., USA
Effects of Inhibition of TGF-ß on Tumorigenesis

S. Kyun Lim, University of Wisconsin-Madison, USA
Short Talk: Inhibition of TGF-ß Signaling Using Constrained Peptides and Small Molecules

09:20—09:40
Coffee Break

Longs Foyer
16:30—17:00
Coffee & Snacks Available

Longs Foyer
17:00—19:00
Therapeutic Strategies for Interfering with TGF-ß Signal Transduction Pathways
Meeting has ended...abstracts no longer viewable online.

Longs
* Jonathan M. Yingling, Idera Pharmaceuticals, Inc., USA
In Vivo Analysis of TGF-ß Receptor Kinase Inhibitors in Fibrosis and Cancer

Andrew A. Protter, Medivation, Inc., USA
ALK5 Kinase Inhibitors for Fibrosis and Cancer

Nicholas J. Laping, GlaxoSmithKline, USA
ALK5 Kinase Inhibitors as Potential Treatment for Fibrosis and Uterine Fibroids

Leona E. Ling, Biogen Idec, USA
Short Talk: Therapeutic Activity of a TBR1 Kinase Inhibitor in a Vascular Fibrosis Model

19:00—20:00
Social Hour

Grays
20:00—23:00
Entertainment

Grays

SATURDAY, APRIL 2

 
Departure


*Session Chair †Invited, not yet responded.



We gratefully acknowledge support for this conference from:


Directors' Fund


These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.



We gratefully acknowledge additional support for this conference from:

Genzyme Corporation Novartis Institutes for BioMedical Research

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



Antisense Pharma GmbH


Educational grant from Lilly USA, LLC


Genentech, Inc.


Genzyme Corporation


GlaxoSmithKline


Janssen Pharmaceuticals, Inc.


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676